Lunai Bioworks (RENB) Stock Price, News & Analysis

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $1.13 to $1.43
• 50-Day Range: $1.30 to $3.15
• 52-Week Range: $1.13 to $21.00
• Volume: 880,400 shs
• Average Volume: 3.75 million shs
• Market Capitalization: $250.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lunai Bioworks Stock Analysis - MarketRank™

Lunai Bioworks scored higher than 12% of companies evaluated by MarketBeat, and ranked 903rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lunai Bioworks.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lunai Bioworks is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lunai Bioworks is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lunai Bioworks has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Lunai Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Lunai Bioworks has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lunai Bioworks has recently increased by 9.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lunai Bioworks does not currently pay a dividend.

Dividend Growth

Lunai Bioworks does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.82% of the float of Lunai Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Lunai Bioworks has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lunai Bioworks has recently increased by 9.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.25

News Sentiment

Lunai Bioworks has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lunai Bioworks this week, compared to 2 articles on an average week.

Search Interest

13 people have searched for RENB on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lunai Bioworks insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.50% of the stock of Lunai Bioworks is held by insiders.

Percentage Held by Institutions

71.41% of the stock of Lunai Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed this year?

Lunai Bioworks' stock was trading at $8.3550 at the beginning of the year. Since then, RENB stock has decreased by 81.6% and is now trading at $1.5410.

How were Lunai Bioworks' earnings last quarter?

Lunai Bioworks Inc. (NASDAQ:RENB) announced its quarterly earnings data on Wednesday, February, 19th. The company reported ($0.20) earnings per share (EPS) for the quarter.

When did Lunai Bioworks' stock split?

Shares of Lunai Bioworks reverse split before market open on Monday, September 29th 2025.The 1-10 reverse split was announced on Wednesday, September 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Lunai Bioworks?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lunai Bioworks own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lunai Bioworks investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 10/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RENB
• CIK: 1527728
• Web: www.enochianbio.com
• Phone: 305-918-1980
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.38%
• Return on Assets: -47.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 1.73

Miscellaneous

• Outstanding Shares: 162,390,000
• Free Float: 171,258,000
• Market Cap: $250.24 million
• Optionable: Optionable
• Beta: 0.54